| Schizophrenia
Aristada & Aristada Initio vs Cobenfy
Side-by-side clinical, coverage, and cost comparison for schizophrenia.Deep comparison between: Aristada vs Cobenfy with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCobenfy has a higher rate of injection site reactions vs Aristada based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Cobenfy but not Aristada, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Aristada
Cobenfy
At A Glance
IM injection
Monthly to every 2 months
Dopamine D2 partial agonist
Oral
Twice daily
Muscarinic agonist/antagonist combination
Indications
- Schizophrenia
- Schizophrenia
Dosing
Schizophrenia 441 mg, 662 mg, or 882 mg monthly, 882 mg every 6 weeks, or 1064 mg every 2 months via IM injection into the deltoid (441 mg only) or gluteal muscle; initiate with ARISTADA INITIO 675 mg plus a single 30 mg oral aripiprazole dose, or supplement with 21 consecutive days of oral aripiprazole concomitant with the first injection.
Schizophrenia Starting dose 50 mg/20 mg orally twice daily for at least 2 days, then 100 mg/20 mg twice daily for at least 5 days; may increase to 125 mg/30 mg twice daily based on tolerability and response (maximum dose); take at least 1 hour before or 2 hours after a meal; do not open capsules. Geriatric patients: start at 50 mg/20 mg twice daily, maximum 100 mg/20 mg twice daily.
Contraindications
- Known hypersensitivity reaction to aripiprazole (reactions have ranged from pruritus/urticaria to anaphylaxis)
- Urinary retention
- Moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment
- Gastric retention
- History of hypersensitivity to COBENFY or trospium chloride
- Untreated narrow-angle glaucoma
Adverse Reactions
Most common (>=5%) Akathisia
Serious Neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, leukopenia, neutropenia, agranulocytosis, seizures, orthostatic hypotension
Postmarketing Anaphylactic reaction, angioedema, pathological gambling, drug reaction with eosinophilia and systemic symptoms (DRESS), oculogyric crisis, fecal incontinence
Most common (>=5%) Nausea, dyspepsia, constipation, vomiting, hypertension, abdominal pain, diarrhea, tachycardia, dizziness, gastroesophageal reflux disease
Serious Urinary retention, liver enzyme elevations, increases in heart rate, angioedema
Postmarketing Chest pain, hypertensive crisis, palpitations, supraventricular tachycardia, syncope, gastritis, rash, rhabdomyolysis, confusion, delirium, hallucinations, somnolence, vision abnormal, angioedema, anaphylactic reaction, Stevens-Johnson syndrome (reported with trospium chloride component)
Pharmacology
Aripiprazole lauroxil is a prodrug of aripiprazole that, following IM injection, undergoes enzyme-mediated hydrolysis to yield aripiprazole, which exerts its effects through partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors.
Xanomeline is a muscarinic agonist with preferential activity at M1 and M4 receptors in the central nervous system, where its efficacy in schizophrenia is thought to arise; trospium chloride is a peripheral muscarinic antagonist included to reduce cholinergic adverse effects.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Aristada
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (4/12) · Qty limit (11/12)
Cobenfy
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (8/12) · Qty limit (11/12)
UnitedHealthcare
Aristada
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Cobenfy
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (2/8)
Humana
Aristada
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (3/3)
Cobenfy
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$10/fillfill
Aristada Co-pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0/fillfill
Cobenfy Copay Assistance ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AristadaView full Aristada profile
CobenfyView full Cobenfy profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.